Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin

Pediatric Infectious Disease Journal

Volumn 19, Issue 12 SUPPL., 2000, Pages

  Guay, D R P ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cefdinir; Cephalosporins; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTIBIOTIC AGENT; CEFACLOR; CEFALEXIN; CEFDINIR; CEFIXIME; CEFPODOXIME; CEFTIBUTEN; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; FERROUS SULFATE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CHILD; DRUG BIOAVAILABILITY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL;

ADULT; BACTERIA; BACTERIAL INFECTIONS; CEPHALOSPORINS; CHILD; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 0034538365     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200012001-00002     Document Type: Article

References (68)

1. Oral cephalosporins: Focus on new agents
2. Use of oral cephalosporins in infants and children
3. Reasons for failures in penicillin treatment of streptococcal tonsillitis and possible alternatives
4. Antibiotic resistance of microorganisms involved in ear, nose and throat infections
5. Empiric antibiotic selection criteria for respiratory infections in pediatric practice
6. Management of otitis media
7. Short-course antimicrobial therapy for upper respiratory infections
8. The management of common infections in ambulatory children
9. The role of newer oral cephalosporins, fluoroquinolones, and macrolides in the treatment of pediatric infections
10. Perspectives on newer oral antimicrobials: What do they add?
11. Morphological alterations of Staphylococcus aureus and Streptococcus pyogenes exposed to cefdinir, a new oral broad-spectrum cephalosporin
12. In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem
13. In-vitro and in-vivo antibacterial activities of CS-834, a new oral carbapenem
14. Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin
15. The in-vitro activity of cefdinir (FK482), a new oral cephalosporin
16. In vitro activity of cefdinir (FK482, PD134393, CI-983): A new orally active cephalosporin
17. Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines
18. In vitro activity evaluations of cefdinir (FK482, CI-983, and PD 134393). A novel orally administered cephalosporin
19. In vitro activity of cefdinir (FK482) and ten other antibiotics against Gram-positive and Gram-negative bacteria isolated from adult and pediatric patients
20. Pharmacokinetics of cefdinir and its transfer to dialysate in patients with chronic renal failure undergoing continuous ambulatory peritoneal dialysis
21. FK482, a new orally active cephalosporin, synthesis and biological properties
22. Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides
23. RU29246, the active compound of the cephalosporin-prodrug-ester HR916: I. Antibacterial activity in vitro
24. Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, Gram-negative bacilli and respiratory tract pathogens
25. Cefdinir: In vitro activity study and effect of human serum
26. In vitro antibacterial activity of FK482, a new orally active cephalosporin
27. In vitro evaluation of cefdinir (FK482), a new oral cephalosporin with enhanced antistaphylococcal activity and beta-lactamase stability
28. In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem
29. In vivo antibacterial activities of sanfetrinem cilexetil, a new oral tricyclic antibiotic
30. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor, and cefadroxil
31. Studies on novel 3-isoxazolylvinyl-cephalosporins: II. Synthesis and biological activity of 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido] derivatives
32. In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production
33. In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin, in the fields of obstetrics and gynecology
34. In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir
35. Activities of RPR 10697 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin,susceptible and -resistant pneumococci
36. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four betalactam antibiotics
37. Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829
38. Etiological study of diarrheal patients in Vientiane, Lao People's Democratic Republic
39. Susceptibility testing interpretive criteria and drug stability for cefdinir, cefetamet, and cefpodoxime against Neisseria gonorrhoeae
40. The sensitivity of clinical bacteria isolated in Scotland to the oral cephalosporin, cefdinir
41. Comparative in-vitro activity of cefdinir against multiresistant Haemophilus influenzae
42. Increasing prevalence of ampicillin-resistant, non-beta-lactamase-producing strains of Haemophilus influenzae in children in Japan
43. Antimicrobial activity of three investigational cephalosporins (BK-218, cefdinir, and RU29246) against Legionella
44. Antistaphylococcal activity of cefdinir, a new oral third-generation cephalosporin, alone and in combination with other antibiotics, at supra- and sub-MIC levels
45. Post-antibiotic effects of cefdinir on Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus pyogenes
46. Bactericidal activity and postantibiotic effect of cefdinir (CI983, FK482) against selected pathogens
47. Stability of cefdinir (CI-983, FK482) to extended-spectrum plasmid-mediated beta-lactamases
48. Activities of Other beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases
49. Interaction of cefdinir with beta-lactamases
50. Cefdinir (CI-983), a new oral amino-2-thiazolyl cephalosporin, inhibits human neutrophil myeloperoxidase in the extracellular medium but not the phagolysosome
51. In vitro activity of two new oral cephalosporins, cefixime and cefdinir (CI983), on human peripheral mononuclear and polymorphonuclear neutrophil functions
52. Cefdinir-mediated modification of the susceptibility of bacteria to the antibacterial activity of human serum and polymorphonuclear neutrophils
53. Tests for susceptibility of Streptococcus pneumoniae to cefdinir: Proposed interpretive criteria and quality control parameters for broth microdilution and disc diffusion methods
54. Quality control guidelines for cefdinir, cefepime, cefetamet, cefmetazole, cefpodoxime, cefprozil, and clinafloxacin (CI-960) for various National Committee for Clinical Laboratory Standards susceptibility testing methods
55. MIC and disk diffusion quality control guidelines for Neisseria gonorrhoeae susceptibility tests of cefdinir, cefetamet, CI-960, fleroxacin, lomefloxacin, and temafloxacin
56. Disk diffusion quality control guidelines for Haemophilus susceptibility tests using cefdinir, CI-960, fleroxacin, temafloxacin, and trospectomycin
57. MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin
58. Haemophilus test medium interpretive criteria for disk diffusion susceptibility tests with cefdinir, cefetamet, cefmetazole, cefpodoxime, cefdaloxime (RU 29246, HR-916 metabolite), and trospectomycin
59. Reproducibility of broth microdilution and disk diffusion susceptibility tests of nine antimicrobial agents against Streptococcus pneumoniae ATCC 49619
60. Interpretive criteria for disk diffusion tests using 5-microgram cefdinir disks with rapidly growing clinical isolates
61. Suction-induced blister fluid penetration of cefdinir in healthy volunteers following ascending oral doses
62. Distribution of cefdinir, a third generation cephalosporin antibiotic, in serum and pulmonary compartments
63. Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients
64. Impairment of cefdinir absorption by iron ion
65. A study of 5-day cefdinir treatment for streptococcal pharyngitis in children
66. Study of the use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients
67. Cefdinir versus amoxicillin/clavulanic acid in the treatment of suppurative acute otitis media in children